These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 8986762)
1. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Miroy GJ; Lai Z; Lashuel HA; Peterson SA; Strang C; Kelly JW Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15051-6. PubMed ID: 8986762 [TBL] [Abstract][Full Text] [Related]
2. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Peterson SA; Klabunde T; Lashuel HA; Purkey H; Sacchettini JC; Kelly JW Proc Natl Acad Sci U S A; 1998 Oct; 95(22):12956-60. PubMed ID: 9789022 [TBL] [Abstract][Full Text] [Related]
3. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248 [TBL] [Abstract][Full Text] [Related]
4. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Lashuel HA; Lai Z; Kelly JW Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152 [TBL] [Abstract][Full Text] [Related]
5. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Lai Z; Colón W; Kelly JW Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594 [TBL] [Abstract][Full Text] [Related]
6. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Kelly JW; Colon W; Lai Z; Lashuel HA; McCulloch J; McCutchen SL; Miroy GJ; Peterson SA Adv Protein Chem; 1997; 50():161-81. PubMed ID: 9338081 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. Green NS; Palaninathan SK; Sacchettini JC; Kelly JW J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036 [TBL] [Abstract][Full Text] [Related]
8. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer. Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization. Raghu P; Reddy GB; Sivakumar B Arch Biochem Biophys; 2002 Apr; 400(1):43-7. PubMed ID: 11913969 [TBL] [Abstract][Full Text] [Related]
10. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Miller SR; Sekijima Y; Kelly JW Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122 [TBL] [Abstract][Full Text] [Related]
11. The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Morais-de-Sá E; Neto-Silva RM; Pereira PJ; Saraiva MJ; Damas AM Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):512-9. PubMed ID: 16627944 [TBL] [Abstract][Full Text] [Related]
12. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR). Ciccone L; Nencetti S; Rossello A; Stura EA; Orlandini E J Enzyme Inhib Med Chem; 2016; 31(sup1):40-51. PubMed ID: 27067161 [TBL] [Abstract][Full Text] [Related]
14. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis. Liang Y; Ore MO; Morin S; Wilson DJ Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799 [TBL] [Abstract][Full Text] [Related]
15. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Green NS; Foss TR; Kelly JW Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386 [TBL] [Abstract][Full Text] [Related]
16. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320 [TBL] [Abstract][Full Text] [Related]
17. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Gustavsson A; Jahr H; Tobiassen R; Jacobson DR; Sletten K; Westermark P Lab Invest; 1995 Nov; 73(5):703-8. PubMed ID: 7474944 [TBL] [Abstract][Full Text] [Related]
18. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953 [TBL] [Abstract][Full Text] [Related]
19. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. Morais-de-Sá E; Pereira PJ; Saraiva MJ; Damas AM J Biol Chem; 2004 Dec; 279(51):53483-90. PubMed ID: 15469931 [TBL] [Abstract][Full Text] [Related]
20. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. Ferreira N; Saraiva MJ; Almeida MR FEBS Lett; 2011 Aug; 585(15):2424-30. PubMed ID: 21740906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]